Scarica l'app Stockscreener
61.57
1.68%
1.02
Precedente Chiudi:
$60.55
Aprire:
$61
Volume 24 ore:
1.09M
Relative Volume:
1.05
Capitalizzazione di mercato:
$5.09B
Reddito:
-
Utile/perdita netta:
$-64.16M
Rapporto P/E:
-48.47
EPS:
-1.2702
Flusso di cassa netto:
$-69.06M
1 W Prestazione:
+8.04%
1M Prestazione:
+18.45%
6M Prestazione:
+99.00%
1 anno Prestazione:
+148.27%
Intervallo 1D:
$60.55
$63.58
Intervallo di 1 settimana:
$55.15
$63.58
Portata 52W:
$14.80
$63.58
Cg Oncology Inc Stock (CGON) Company Profile
Nome
Cg Oncology Inc
Settore
Industria
Telefono
(949) 419-6203
Indirizzo
400 SPECTRUM CENTER DRIVE, IRVINE
Compare CGON vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
61.57 | 5.00B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-11 | Iniziato | Wedbush | Outperform |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-10-08 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2025-05-02 | Iniziato | JP Morgan | Overweight |
| 2025-04-16 | Iniziato | Scotiabank | Sector Perform |
| 2025-01-07 | Iniziato | TD Cowen | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-09-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-28 | Iniziato | ROTH MKM | Buy |
| 2024-06-28 | Iniziato | BofA Securities | Buy |
| 2024-02-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-02-20 | Iniziato | Goldman | Neutral |
| 2024-02-20 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-14 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Cg Oncology Inc Borsa (CGON) Ultime notizie
Rafferty Asset Management LLC Lowers Stock Position in CG Oncology, Inc. $CGON - MarketBeat
Stock Traders Buy High Volume of Call Options on CG Oncology (NASDAQ:CGON) - MarketBeat
CG Oncology, Inc. $CGON Stock Holdings Trimmed by TD Asset Management Inc - MarketBeat
Lifesci Capital Predicts Stronger Earnings for CG Oncology - MarketBeat
CG Oncology (NASDAQ:CGON) Sets New 12-Month HighTime to Buy? - MarketBeat
CG Oncology, Inc. (CGON) Stock Analysis: A 39% Potential Upside in the Battle Against Bladder Cancer - DirectorsTalk Interviews
CG Oncology stock hits all-time high at 60.01 USD By Investing.com - Investing.com Australia
CG Oncology stock hits all-time high at 60.01 USD - Investing.com
CG Oncology (CGON) Valuation Check As Bladder Cancer Trial Timelines Accelerate And Cash Runway Extends To 2029 - Sahm
NMIBC Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Ferring Pharmaceuticals, FKD Therapies Oy, ImmunityBio, CG Oncology, Pfizer, UroGen Pharma, Janssen R&D - StreetInsider
CGON Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Buy Rating on CG Oncology Driven by PIVOT-006 Differentiation and 2026 Clinical, Regulatory Catalysts Supporting Favorable Risk–Reward - TipRanks
CGON: Credo shows high efficacy and durability, with regulatory and commercial plans advancing - TradingView
H.C. Wainwright raises CG Oncology stock price target to $80 By Investing.com - Investing.com Canada
H.C. Wainwright raises CG Oncology stock price target to $80 - Investing.com
AI Stocks: What is the dividend yield of CG Oncology IncJuly 2025 PostEarnings & Verified Swing Trading Watchlists - baoquankhu1.vn
Vanguard Group Inc. Has $264.93 Million Stock Position in CG Oncology, Inc. $CGON - MarketBeat
The Bull Case For CG Oncology (CGON) Could Change Following Surging Revenue And Deeper 2025 Losses – Learn Why - simplywall.st
What Analysts Are Saying About CG Oncology Stock - Benzinga
HC Wainwright Issues Positive Forecast for CG Oncology (NASDAQ:CGON) Stock Price - MarketBeat
CGON Stock: HC Wainwright & Co. Maintains Rating, Raises Price T - GuruFocus
Why CG Oncology Stock Is Suddenly Surging Higher - TipRanks
CG Oncology (NASDAQ:CGON) Trading Up 5.6% Following Strong Earnings - MarketBeat
CG Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
CG Oncology Q4 Net Loss Widens; Expects Cash Runway Into 2029 - marketscreener.com
CG Oncology, Inc. SEC 10-K Report - TradingView
CGON: Net loss rose to $161M as R&D and G&A costs increased; $742M cash on hand funds 12+ months - TradingView
CG Oncology (CGON) builds late-stage bladder cancer franchise on cretostimogene - Stock Titan
CGON: 2025 net loss widened to $161M as R&D ramped up, with $903M cash to fund operations into 2029 - TradingView
CG Oncology (NASDAQ: CGON) widens 2025 loss but secures $903M cash and nears Phase 3 data - Stock Titan
CG Oncology Reports Strong Cash Position and Upcoming Milestones for Cretostimogene Development in NMIBC Trials - Quiver Quantitative
Earnings Flash (CGON) CG Oncology Posts 2025 Total Revenue $4M, vs. FactSet Est of $2.8M - marketscreener.com
CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates - The Manila Times
CG Oncology lines up 2026 NMIBC trial readouts with $903M cash - Stock Titan
CG Oncology Q4 Earnings Report: What Investors Need to Know - Sahm
According to the latest financial data from CG Oncology Inc., the company currently holds a total of $903 millions in cash, cash equivalents, and marketable securities. - Bitget
CG Oncology, Inc. unveils five cretostimogene research posters at ASCO GU in San Francisco - Traders Union
CG Oncology (NASDAQ:CGON) Sets New 52-Week HighTime to Buy? - MarketBeat
CG Oncology, Inc. (CGON) Stock Analysis: Unveiling a Potential 36.95% Upside in the Biotech Sector - DirectorsTalk Interviews
JP Morgan Initiates Coverage of CG Oncology (CGON) with Overweight Recommendation - MSN
CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference - The Manila Times
CG Oncology leaders at TD Cowen health conference, webcast March 2 - Stock Titan
Assessing CG Oncology (CGON) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
CG Oncology stock hits all-time high at 57.92 USD By Investing.com - Investing.com India
Analysts Are Bullish on These Healthcare Stocks: CG Oncology, Inc. (CGON), Qiagen (QGEN) - The Globe and Mail
CG Oncology (NASDAQ:CGON) Hits New 12-Month HighHere's Why - MarketBeat
What are CG Oncology Inc.’s technical support levels2025 Volume Leaders & High Accuracy Investment Signals - mfd.ru
CG Oncology stock hits all-time high at 57.92 USD - Investing.com South Africa
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale - Yahoo Finance
Muscle Invasive Bladder Cancer Market: Pharma Pipeline Fuels Rapid Expansion by 2034 – DelveInsight | CG Oncology, Pfizer, UroGen Pharma, Janssen R&D, Protara Therapeutics, Binhui Biopharmaceutical - Barchart.com
CenterBook Partners LP Has $15.92 Million Stake in CG Oncology, Inc. $CGON - MarketBeat
Cg Oncology Inc Azioni (CGON) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
6.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):